Otonomy Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
37,359.00
156,033.00
184,836.00
196,378.00
120,004.00
97,284
Total Accounts Receivable
-
-
-
91.00
107.00
108
Inventories
-
-
-
1,435.00
6.00
-
Other Current Assets
1,654.00
1,669.00
3,319.00
4,316.00
2,328.00
2,677
Total Current Assets
39,013.00
157,702.00
188,155.00
202,220.00
122,445.00
100,069
Net Property, Plant & Equipment
683.00
1,257.00
3,094.00
4,977.00
4,679.00
3,996
Total Investments and Advances
-
-
695.00
697.00
1,158.00
696
Other Assets
61.00
205.00
1,086.00
702.00
82.00
231
Total Assets
39,757.00
159,164.00
193,030.00
208,596.00
128,364.00
104,992
Accounts Payable
-
-
-
1,292.00
961.00
Other Current Liabilities
2,715.00
5,417.00
11,291.00
13,941.00
7,230.00
Total Current Liabilities
2,715.00
5,417.00
11,291.00
15,233.00
8,191.00
Long-Term Debt
646.00
-
-
-
-
Other Liabilities
220.00
134.00
205.00
626.00
2,894.00
Total Liabilities
3,581.00
5,551.00
11,496.00
15,859.00
11,085.00
Common Equity (Total)
58,977.00
153,613.00
181,534.00
192,737.00
117,279.00
Total Shareholders' Equity
36,176.00
153,613.00
181,534.00
192,737.00
117,279.00
Total Equity
36,176.00
153,613.00
181,534.00
192,737.00
117,279.00
Liabilities & Shareholders' Equity
39,757.00
159,164.00
193,030.00
208,596.00
128,364.00
Preferred Stock (Carrying Value)
95,153.00
-
-
-
-

About Otonomy

View Profile
Address
4796 Executive Drive
San Diego California 92121
United States
Employees -
Website http://www.otonomy.com
Updated 07/08/2019
Otonomy, Inc. is a biopharmaceutical company, which engages in the research, development, and manufacture of therapeutics for otology. The firm's portfolio includes therapeutics for diseases and disorders of the ear such as Ménière's disease, tinnitus, synaptopathy hearing loss, cisplatin-induced loss, severe hearing loss, TTP surgery, and acute otitis externa. It operates under the Otiprio brand.